Akeso

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $5B

Website

Clinical Trials

A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer

Phase 3

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
Drug: Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine
Drug: Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: Akeso

Target Recruit Count: 999

Registration Number: NCT06953999

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Phase 3

Not yet recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: AK112
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Leucovorin and 5-FU
Drug: Bevacizumab

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: Akeso

Target Recruit Count: 560

Registration Number: NCT06951503

Locations: 🇨🇳
The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China

A Clinical Study of AK139 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Subjects

Interventions: Drug: AK111
Drug: Placebo

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Akeso

Target Recruit Count: 48

Registration Number: NCT06947109

AK129 Combination Therapy for Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer Stage IIIB/IV
Head and Neck Squamous Cell Carcinoma (HNSCC)
Colorectal Adenocarcinoma
Advanced Solid Tumors

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Chemotherapy
Drug: AK129(dose 1)
Drug: Cis-platinum
Drug: Carboplatin
Drug: Paclitaxel
Drug: 5-FU (5-fluorouracil)
Drug: Docetaxel
Drug: AK129(dose 2)
Drug: AK129(RP2D)
Drug: Penpulimab

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: Akeso

Target Recruit Count: 230

Registration Number: NCT06943820

Locations: 🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

Phase 1

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: AK112
Drug: AK130

First Posted Date: 2025-04-22

Last Posted Date: 2025-04-22

Lead Sponsor: Akeso

Target Recruit Count: 135

Registration Number: NCT06938321

Locations: 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: AK146D1 for injection

First Posted Date: 2025-04-16

Last Posted Date: 2025-04-16

Lead Sponsor: Akeso

Target Recruit Count: 48

Registration Number: NCT06929663

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Ivonescimab, docetaxel
Drug: Placebo, docetaxel

First Posted Date: 2025-04-15

Last Posted Date: 2025-05-01

Lead Sponsor: Akeso

Target Recruit Count: 536

Registration Number: NCT06928389

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Phase 1

Not yet recruiting

Conditions: Pancreas Cancer
Pancreas Cancer, Duct Cell Adenocarcinoma

Interventions: Biological: AK154
Biological: Cadonilimab
Biological: Ivonescimab (SMT112 or AK112) Injection
Drug: mFOLFORINOX

First Posted Date: 2025-04-06

Last Posted Date: 2025-04-06

Lead Sponsor: Akeso

Target Recruit Count: 60

Registration Number: NCT06913218

Locations: 🇨🇳
Department of Pancreatic Surgery,Fudan University Shanghai Cancer Center, Shanghai, Xuhui, China

AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Phase 1

Not yet recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN)

Interventions: Drug: AK135

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: Akeso

Target Recruit Count: 85

Registration Number: NCT06860789

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, China
🇨🇳
Shanghai GoBroad Cancer Hospital, Shanghai, China

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Phase 3

Not yet recruiting

Conditions: Triple-Negative Breast Cancer (TNBC)

Interventions: Drug: AK112
Drug: Nab-paclitaxel
Drug: Placebo

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: Akeso

Target Recruit Count: 416

Registration Number: NCT06767527

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Home Terms & Conditions Privacy Policy